Clinical Overview
Flibanserin is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first and only FDA-approved medication specifically for female sexual dysfunction, working through a unique mechanism involving serotonin receptors rather than hormonal pathways.
Primary Clinical Applications
Flibanserin is specifically indicated for acquired, generalized HSDD in premenopausal women, characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or effects of a medication or other drug substance.
Mechanism and Clinical Effects
Flibanserin acts as a 5-HT1A receptor agonist and 5-HT2A receptor antagonist, modulating serotonin, dopamine, and norepinephrine in brain regions associated with sexual response. This mechanism aims to restore the balance between excitatory and inhibitory factors affecting sexual desire.
Safety and Administration Requirements
Flibanserin requires bedtime dosing due to sedation and hypotension risks. It has significant contraindications with alcohol and certain medications. The medication is available only through a restricted program (REMS) requiring prescriber and pharmacy certification due to safety concerns.
Prescribing Information
Dosing & Administration
Hypoactive Sexual Desire Disorder – Premenopausal Women:
- Dose: 100 mg once daily at bedtime
- Duration: Reassess after 8 weeks of treatment
- Discontinuation: If no improvement after 8 weeks, discontinue
Administration Requirements:
- Take at bedtime only
- Avoid alcohol during treatment
- Available only through REMS program
- Take with or without food
Indications
- Treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women
- Must be acquired, generalized HSDD not due to other causes
Contraindications
- Alcohol use during treatment
- Hepatic impairment
- Strong or moderate CYP3A4 inhibitors
- Hypersensitivity to flibanserin
Warnings & Precautions
- Boxed Warning: Severe hypotension and syncope, especially with alcohol; CNS depression
- Hypotension and syncope: Risk increased with alcohol, CYP3A4 inhibitors
- CNS depression: Sedation, somnolence particularly within 6 hours of dosing
- REMS program: Restricted distribution due to safety concerns
- Driving impairment: May impair ability to drive or operate machinery
Drug Interactions
- Alcohol: Contraindicated – significantly increases hypotension and syncope risk
- Strong CYP3A4 inhibitors: Contraindicated (ketoconazole, itraconazole)
- Moderate CYP3A4 inhibitors: Contraindicated (fluconazole, grapefruit juice)
- CYP3A4 inducers: May reduce flibanserin effectiveness
- CNS depressants: Enhanced sedation
Adverse Reactions
Common (≥2%):
- Dizziness, somnolence, nausea, fatigue, insomnia
- Dry mouth, hypotension, syncope
Serious:
- Severe hypotension, syncope (especially with alcohol)
- CNS depression, accidental injury
Special Populations
- Hepatic Impairment: Contraindicated in any degree of impairment
- Renal Impairment: No dose adjustment needed
- Postmenopausal Women: Not indicated, safety and efficacy not established
- REMS Requirements: Prescriber and pharmacy certification required
- Pregnancy: Category N/A – not indicated in pregnant women
</u
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
